Intuitive Surgical, Inc. $ISRG Holdings Boosted by PGGM Investments

PGGM Investments lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 21.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,273 shares of the medical equipment provider’s stock after purchasing an additional 10,848 shares during the quarter. PGGM Investments’ holdings in Intuitive Surgical were worth $27,850,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ISRG. Vanguard Group Inc. increased its position in Intuitive Surgical by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after purchasing an additional 670,302 shares during the last quarter. State Street Corp increased its position in Intuitive Surgical by 1.2% during the second quarter. State Street Corp now owns 15,552,203 shares of the medical equipment provider’s stock worth $8,451,223,000 after buying an additional 182,871 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Intuitive Surgical by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 8,188,685 shares of the medical equipment provider’s stock valued at $4,429,590,000 after acquiring an additional 109,904 shares during the last quarter. Norges Bank bought a new stake in Intuitive Surgical during the second quarter worth approximately $2,569,260,000. Finally, Invesco Ltd. boosted its holdings in Intuitive Surgical by 4.8% during the second quarter. Invesco Ltd. now owns 4,421,133 shares of the medical equipment provider’s stock valued at $2,402,488,000 after acquiring an additional 201,159 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Intuitive Surgical in a report on Monday, December 29th. HSBC increased their price objective on shares of Intuitive Surgical from $595.00 to $644.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Royal Bank Of Canada lifted their target price on shares of Intuitive Surgical from $625.00 to $650.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Truist Financial boosted their price target on Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, Zacks Research upgraded Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 24th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $622.17.

Intuitive Surgical Stock Down 1.0%

NASDAQ ISRG opened at $541.34 on Friday. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00. The company has a market capitalization of $194.06 billion, a PE ratio of 71.61, a price-to-earnings-growth ratio of 4.44 and a beta of 1.67. The firm’s 50 day moving average is $566.82 and its 200-day moving average is $512.30.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.41. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The firm had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the previous year, the business posted $1.84 earnings per share. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 464 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $548.49, for a total transaction of $254,499.36. Following the sale, the senior vice president directly owned 131 shares in the company, valued at $71,852.19. This represents a 77.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Gary S. Guthart sold 22,806 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $570.89, for a total value of $13,019,717.34. Following the transaction, the insider directly owned 2,694 shares of the company’s stock, valued at $1,537,977.66. This trade represents a 89.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 114,007 shares of company stock valued at $63,533,844 over the last three months. 0.70% of the stock is owned by insiders.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Quarterly and full‑year beats — Intuitive reported preliminary Q4 and FY‑2025 results that topped consensus, with procedure growth, revenue and placements coming in ahead of expectations; this underpins the company’s revenue momentum. Intuitive Surgical Crushed Fourth-Quarter Forecasts. So Why Did Shares Dive?
• Positive Sentiment: Analyst support and bullish notes — Multiple firms (including Bernstein and William Blair) are maintaining buy ratings and emphasizing DV5 adoption and the innovation pipeline, which supports upside over the medium term. Bernstein Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
• Positive Sentiment: Clinical pipeline update — A Phase 3 update on IS‑001 (an imaging-driven safety play) could add optionality if results are favorable; this is a longer‑horizon positive catalyst. Intuitive Surgical’s IS-001 Phase 3 Update
• Neutral Sentiment: Investor presentations and disclosures — Management presented at the J.P. Morgan Healthcare Conference and provided slides/transcript that reiterate strategy and product rollout plans; useful for modeling but did not change the near‑term story. Intuitive Surgical Presents at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: da Vinci 5 international rollout — The new DV5 expands the addressable market, but adoption overseas could be slowed by pricing, budget and reimbursement hurdles; positive long term but uncertain timing. da Vinci 5 Expands Globally: Can ISRG Beat Overseas Cost Hurdles?
• Negative Sentiment: Softer 2026 outlook — Management’s 2026 guidance and da Vinci growth projection were softer than some investors expected, which prompted the stock pullback despite the Q4 beat. Intuitive Surgical Sets Softer 2026 Outlook
• Negative Sentiment: Valuation and growth concerns — With a high multiple (e.g., elevated P/E) investors are sensitive to any slowdown; commentary and headlines focused on missed growth expectations amplified the sell‑off. Why Intuitive Surgical Stock Dropped Today

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.